Abstract
A series of triazolo-pyridazinone derivatives were prepared through the standard click reactions of 4,6-diphenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-one 1, possessing a free terminal alkyne group with a selection of substituted aryl azides 2-9. The cytotoxicity and in vitro anticancer investigation of the new compounds were conducted against four different human tumor cell lines, including breast adenocarcinoma MCF-7, hepatocellular carcinoma HepG2, lung cancer A549 and colon cancer HCT116 cell lines. The results showed that the compounds exerted their actions in MCF-7 and A549 via inhibition of the urokinase activity. The compound 17 showed potent anticancer activity compared with the activity of the standard anticancer drug, doxorubicin. Molecular docking studies were performed to support the activity data and predict the plausible mechanisms of the ligand-protein interactions.
Keywords: Trizolo-pyridazinone, anticancer, urokinase, MCF-7, HepG2, A549, HCT116.
Graphical Abstract
Current Organic Chemistry
Title:Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds
Volume: 22 Issue: 23
Author(s): Tamer El Malah*, Hany F. Nour, Oussama Dehbi, Farouk M.E. Abdel-Megeid, Abeer Essam El-Din Mahmoud, Mamdouh Moawad Ali and Salwa M. Soliman
Affiliation:
- National Research Centre, Chemical Industries Research Division, Photochemistry Department, 33 El Buhouth Street, P.O. Box 12622, Giza,Egypt
Keywords: Trizolo-pyridazinone, anticancer, urokinase, MCF-7, HepG2, A549, HCT116.
Abstract: A series of triazolo-pyridazinone derivatives were prepared through the standard click reactions of 4,6-diphenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-one 1, possessing a free terminal alkyne group with a selection of substituted aryl azides 2-9. The cytotoxicity and in vitro anticancer investigation of the new compounds were conducted against four different human tumor cell lines, including breast adenocarcinoma MCF-7, hepatocellular carcinoma HepG2, lung cancer A549 and colon cancer HCT116 cell lines. The results showed that the compounds exerted their actions in MCF-7 and A549 via inhibition of the urokinase activity. The compound 17 showed potent anticancer activity compared with the activity of the standard anticancer drug, doxorubicin. Molecular docking studies were performed to support the activity data and predict the plausible mechanisms of the ligand-protein interactions.
Export Options
About this article
Cite this article as:
El Malah Tamer*, Nour F. Hany , Dehbi Oussama, Abdel-Megeid M.E. Farouk , Mahmoud Essam El-Din Abeer , Ali Moawad Mamdouh and Soliman M. Salwa, Click Synthesis, Anticancer Activity and Molecular Docking Studies on Pyridazinone Scaffolds, Current Organic Chemistry 2018; 22 (23) . https://dx.doi.org/10.2174/1385272822666181029111943
DOI https://dx.doi.org/10.2174/1385272822666181029111943 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Medicinal Chemistry Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function
Current Drug Metabolism Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy
Current Drug Targets The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators
Mini-Reviews in Medicinal Chemistry Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Intersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Current Pharmaceutical Biotechnology The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities
Current Molecular Medicine AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design Banking Strategies for Improving the Hematopoietic Stem Cell Content of Umbilical Cord Blood Units for Transplantation
Current Stem Cell Research & Therapy Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial
Reviews on Recent Clinical Trials Personalized Medicine in a Consumer Age
Current Pharmacogenomics and Personalized Medicine DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Recent Advances in the Analyses of Carotenoids and Their Role in Human Health
Current Pharmaceutical Analysis Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Current Cancer Therapy Reviews